The goal of the Developmental Research Program is to identify and support high quality, conceptually innovative translational projects that are not yet mature for full program status despite having outstanding potential. The Developmental Research Program will facilitate the attainment of this objective by 1) coordinating developmental research project selection 2) fostering the success of these projects through monitoring of their progress and 3) establishing institutional and extramural collaborations. Moreover, at the discretion of the Executive Committee of the SPORE, pilot projects which generate promising results can replace SPORE research projects which become funded as independent R01 or POI's projects and replace research projects which fail to show satisfactory progress. The long term goal of the Lymphoma SPORE program is to translate the findings generated by the Developmental Projects into a reduction of the incidence, morbidity and mortality of lymphoma. Specifically, the Developmental Research Program will; 1. Encourage innovative laboratory, population, and clinical studies with translational relevance by providing seed money to investigators 2. Support the evolution of developmental projects by providing intellectual and practical feedback through critical review and monitoring 3. Encourage intra-institutional and extramural collaborations between basic, clinical and population sciences with impact on translational research in lymphoma 4. Contribute to the overall success of the SPORE by providing the Executive Committee with guidance regarding promising projects in City of Hope's lymphoma translational research pipeline

Public Health Relevance

The goal of the Developmental Research Program is to identify and support high quality, conceptually innovative translational projects that are not yet mature for full program status despite having outstanding potential.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA107399-08
Application #
8566757
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
8
Fiscal Year
2013
Total Cost
$35,406
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Budde, Lihua E; Wu, David; Martin, Daniel B et al. (2018) Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 183:601-607
Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60
Herrera, Alex F; Moskowitz, Alison J; Bartlett, Nancy L et al. (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183-1194
Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87
Wang, Xiuli; Walter, Miriam; Urak, Ryan et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 24:106-119
Mei, Matthew G; Cao, Thai M; Chen, Lu et al. (2017) Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant 23:1861-1869
Herrera, Alex F; Mei, Matthew; Low, Lawrence et al. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 35:24-31

Showing the most recent 10 out of 97 publications